Compound Detail
CHEMBL1088751
PH-797804 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL1088751 |
| Name | PH-797804 |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | KCAJXIDMCNPGHZ-UHFFFAOYSA-N |
10
Targets
22
Activities
3
Assay Types
13
PK Parameters
20
Publications
2
Known Names
5
Indications
1
Mechanisms
Molecular Properties
477.3
MW (Da)
4.43
ALogP
4
HBA
1
HBD
60.3
PSA (Ų)
0.59
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| MAP kinase p38 alpha inhibitor | INHIBITOR | Mitogen-activated protein kinase 14 | ✓ | ✓ |
Indications
Arthritis, Rheumatoid Neuralgia, Postherpetic Osteoarthritis Pulmonary Disease, Chronic Obstructive Pain
Activity Summary
IC50 13 meas. best 8.98
Ki 5 meas. best 8.54
Kd 4 meas. best 8.6
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Mitogen-activated protein kinase 14 CHEMBL260 | IC50 | 8.98 | 8.1383 | 1.1 | 6 |
| Mitogen-activated protein kinase 14 CHEMBL260 | Kd | 8.6 | 8.45 | 2.5 | 2 |
| Mitogen-activated protein kinase 14 CHEMBL260 | Ki | 8.54 | 8.39 | 2.9 | 2 |
| NON-PROTEIN TARGET CHEMBL3879801 | IC50 | 8.47 | 8.47 | 3.4 | 2 |
| PBMC CHEMBL613107 | IC50 | 8.47 | 8.145 | 3.4 | 2 |
| U-937 CHEMBL612794 | IC50 | 8.23 | 8.23 | 5.9 | 1 |
| Mitogen-activated protein kinase 11 CHEMBL3961 | Ki | 7.4 | 7.4 | 40.0 | 1 |
| Blood CHEMBL613416 | IC50 | 7.07 | 7.07 | 85.0 | 1 |
| Mitogen-activated protein kinase 11 CHEMBL3961 | Kd | 6.99 | 6.99 | 102.0 | 1 |
| STE20-related kinase adapter protein alpha CHEMBL1795198 | Kd | 6.17 | 6.17 | 672.0 | 1 |
| Rho-associated protein kinase 2 CHEMBL2973 | Ki | 5.3 | 5.3 | 5011.9 | 1 |
| Mitogen-activated protein kinase 12 CHEMBL4674 | Ki | 5.2 | 5.2 | 6309.6 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 4.72 | 4.72 | 18850.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 3.0 | uL.min-1.(10^6cells)-1 | Homo sapiens |
| F | 9.3 | % | Rattus norvegicus |
| F | 23.2 | % | Macaca fascicularis |
| F | 35.7 | % | Rattus norvegicus |
| F | 36.2 | % | Macaca fascicularis |
| F | 59.6 | % | Canis lupus familiaris |
| F | 80.4 | % | Rattus norvegicus |
| F | 100.0 | % | Rattus norvegicus |
| Ka | 1.08 | 10'7/M.s | Homo sapiens |
| T1/2 | 3.93 | hr | Macaca fascicularis |
| T1/2 | 2.6 | hr | Rattus norvegicus |
| T1/2 | 11.4 | hr | Canis lupus familiaris |
| T1/2 | 0.006944 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine